

February 4, 2016  
Symbio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President & Chief Executive Officer

### **Assessment Status of Bendamustine in Europe**

Symbio Pharmaceuticals Limited (Headquarters: Tokyo, “Symbio”) announced today that Symbio received on February 2, 2016 (Tokyo time) a notice from Astellas Pharma GmbH (European subsidiary of Astellas Pharma Inc., Tokyo, Japan (Representative Director and CEO, Hatanaka Yoshihiko)) that it has withdrawn its application for EU marketing authorization of bendamustine to treat first-line Lg-NHL (defined below), on January 27, 2016.

Symbio submitted its supplemental New Drug Application (“sNDA”) to the Pharmaceuticals and Medical Devices Agency (“PMDA”) in Japan for TREAKISYM® (“bendamustine”) in the treatment of first-line low-grade non-Hodgkin’s lymphoma (“Lg-NHL”) and mantle cell lymphoma (“MCL”) on December 24, 2015, with assessment of this sNDA by PMDA underway.

In overseas markets, bendamustine is used for Lg-NHL and MCL indications and there is a strong demand for bendamustine from patients and academic societies in Japan. Symbio will continue to pursue the assessment procedure for its sNDA as planned.

This event will not impact the Company’s current financial forecast.

#### **[Contact]**

Investor Relations  
Tel: +81 (0)3 5472 1125

#### **About Symbio Pharmaceuticals Limited**

Symbio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. The company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.